Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDS 0301

Drug Profile

PDS 0301

Alternative Names: M-9241; MSB0010360; NHS-huIL12; NHS-IL-12; NHS-IL12 human; NHS-IL12/MSB0010360; NHS-muIL12; PDS-01ADC; PDS-0301

Latest Information Update: 16 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoconjugates; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Cholangiocarcinoma; Colorectal cancer
  • Phase I/II Prostate cancer
  • No development reported Solid tumours; Urogenital cancer

Most Recent Events

  • 16 May 2024 PDS Biotechnology plans a pivot trial in Squamous cell cancer (Late-stage disease) in 2024
  • 26 Oct 2023 National Cancer Institute (NCI) plans a phase II trial for Prostate cancer (Combination therapy, Second-line therapy or greater, Recurrent) in USA (SC, Injection) (NCT06096870)
  • 11 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Prostate cancer released by PDS Biotech
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top